Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > Linda's deal sheet - detailed numbers are not the norm
View:
Post by str8goods4achg on Jun 13, 2022 5:28pm

Linda's deal sheet - detailed numbers are not the norm

Take a look at Linda's deal sheet. If deals do have numbers, it is just upfront. A few large deals don't have upfront, half of the midsize deals have upfront and no small deals have numbers. This is normal course of business between big pharma and tiny biotechs. You want to play in the space... you play by big pharma rules. Don't think for a second retail investors can demand anything different. 

In my opinion, this is a very encouraging deal. I have a lot of confidence, given Linda's negotiating experience, that the deal's value is fair and bodes well for SBM future.

Congrats to Sirona's team. It took longer that all of us would have liked, but in the end Well done!


GLTA

Comment by Pandora on Jun 13, 2022 6:19pm
Share price at end of day is 22.5 cents. Up a half cent. Not sure how you categorize your "Well Done" but it seems share price is not one of the factors you consider. It does seem to be a major component for most people here.
Comment by Engcan77 on Jun 13, 2022 7:08pm
I would say "well done" in hiring Linda, and giving Sirona a chance in signing a deal with a top 10 pharma company. Which, as we found out today, she pulled through on her task. Brilliant!! We do not know the terms of the deal, however i would assume she got the best deal that was available to Sirona. This is just my opinion. Her experience gets me to this point. Unless someone else ...more  
Comment by Pandora on Jun 13, 2022 10:45pm
Yes, you've got it. You used the word "hopefully" which I have read many times is not the way to decide in investing in any particular company. It now also falls into that other category of "potential". It has a ton more potential this week than it had last week. I have had numerous companies over the years that were touted to be high in potential but I was very ...more  
Comment by Engcan77 on Jun 14, 2022 12:24am
Hey Pandora. You are right. 'hope' is not a good key factor in deciding if to invest in a company. Although there isn't any gaurantees in the stock market, so 'hope' is maybe what people have, even though they don't want to admit it, or want to use that word.  In this context you are talking about, i believe the deals will come, however was hoping next time they will ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities